https://www.cidrap.umn.edu/all-news
Study shows modest flu vaccine protection against serious disease in kids last season
News brief
42 minutes ago.
Stephanie Soucheray, MA
Topics
Influenza Vaccines
An analysis of US national data finds a flu vaccine effectiveness (VE) against severe outcomes of 48% overall in kids in 2022-23, 53% among preschoolers, and 38% among children aged 9 to 17 years.
The study was published yesterday in Clinical Infectious Diseases. The 2022-23 flu season saw the highest influenza-associated pediatric hospitalization rate in the United States since 2010-11. Most of the illness was caused by the H3N2 strain.
Outcomes were based on pediatric patients seen at 55 hospitals and 107 emergency department (ED) or urgent care (UC) sites through Kaiser Permanente Northern California, Intermountain Healthcare in Utah, and HealthPartners in Minnesota and Wisconsin.
40% protection against hospital cases
The VE for vaccinated children against emergency department and urgent care (ED/UC) visits was 48% (95% confidence interval [CI], 44% to 52%). The study showed that 15.2% of vaccinated kids and 27.1% unvaccinated children made up ED/UC flu patients.
The VE against hospital admission for the flu was 40%. Among kids hospitalized for the flu, 17.5% were vaccinated and 33.4% were unvaccinated. The authors of the study said lower VE may be due to lower vaccine coverage.
The atypically early start of the 2022–2023 influenza season may have resulted in lower observed vaccine coverage.
"The atypically early start of the 2022–2023 influenza season may have resulted in lower observed vaccine coverage, as activity started and peaked before many children and adolescents may have had an opportunity to get vaccinated," they wrote.
High-dose fluvoxamine did not shorten COVID recovery times
News brief
48 minutes ago.
Stephanie Soucheray, MA
Topics
COVID-19
Results from arandomized clinical trial today of 1,208 participants show that high-dose (100-milligram [mg]) fluvoxamine did not improve time to sustained recovery in people with mild to moderate COVID-19 infections.
Fluvoxamine, known as Luvox, is a selective-serotonin reuptake inhibitor. Its potential use for COVID-19 was considered as part of the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV-6) platform, which aims to investigate repurposed medications in the outpatient setting for mild to moderate COVID-19.
The study is published in JAMA.
Participants were enrolled from August 25, 2022, to January 20, 2023, and were 30 years or older with confirmed SARS-CoV-2 infection and at least two acute COVID-19 symptoms for 7 days or less. The participants were randomized to receive fluvoxamine 50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days (601 patients), or a placebo (607).
The primary outcome was time to 3 consecutive days without symptoms.
All patients recovered in 10 to 11 days
The participants' average age was 50 years old, 65.8% were women, 45.5% identified as Hispanic/Latino, and 76.8% reported receiving at least two doses of a SARS-CoV-2 vaccine.
The authors found no differences among the study participants in time to recovery (adjusted hazard ratio, 0.99; 95% credible interval, 0.89 to 1.09), with both groups achieving sustained recovery by days 10 or 11. No participants died during the study, and fluvoxamine was not associated with any adverse events.
In an editorial on the study, two JAMA deputy editors wrote that the ACTIV trial is a success story of the pandemic. They note that shortly after the pandemic began, "the ACTIV platform also quickly began generating key insights for outpatient management of COVID-19 infection, such as the ineffectiveness of ivermectin."
They suggest the model should be used to investigate treatments to several outpatient diseases in addition to COVID.
MSF details mpox outbreak in DR Congo
News brief
Today at 2:47 p.m.
Mary Van Beusekom, MS
Topics
Mpox
Medecins Sans Fronteires (MSF, or Doctors Without Borders) said yesterday that it battled an mpox outbreak in the Democratic Republic of the Congo (DRC)'s Equateur province from August to mid-October.
An emergency team was in the Bolomba health zone in the western DRC to help health officials treat 890 mpox patients, provide education, contain spread of the virus, support 11 remote health centers, and conduct surveillance. Seventy-two patients (8.1%) were hospitalized.
Mpox, which is characterized by skin lesions, can be accompanied by fever, sore throat, muscle aches, or lymph-node pain.
"If the disease is not treated in time, it can lead to complications and death in those affected, especially if their immune system is compromised by other diseases," Raphael Kibwantiaka, head of MSF's emergency response in Bolomba, said in a news release. "As Bolomba was already grappling with a measles epidemic, we intervened against both diseases."
Measles, malnutrition, malaria
The workers followed up with more than 800 mpox patients at home and organized awareness-raising activities in healthcare facilities and the community to prevent disease transmission and combat stigma, "as the disease has highly visible signs on the body, sometimes leading to the rejection of patients by the community," Kibwantiaka said.
The emergency team vaccinated 110,723 children against measles and treated 3,355 others. They also treated 827 malnourished children and 2,583 with malaria.
Staff sometimes had to travel by canoe or motorcycle, often in the rain. Kibwantiaka said Bolomba's remote, densely wooded environment is rich in wildlife, which makes it conducive for the development of diseases with animal origins, such as mpox.
"Eating bushmeat, handling dead animals, and animal bites or scratches encourage the transmission of the virus from animals to humans," he said. "Infected individuals then become highly contagious and need to isolate themselves quickly to prevent widespread transmission."
ALL BRIEFS
Study shows modest flu vaccine protection against serious disease in kids last season
News brief
42 minutes ago.
Stephanie Soucheray, MA
Topics
Influenza Vaccines
An analysis of US national data finds a flu vaccine effectiveness (VE) against severe outcomes of 48% overall in kids in 2022-23, 53% among preschoolers, and 38% among children aged 9 to 17 years.
The study was published yesterday in Clinical Infectious Diseases. The 2022-23 flu season saw the highest influenza-associated pediatric hospitalization rate in the United States since 2010-11. Most of the illness was caused by the H3N2 strain.
Outcomes were based on pediatric patients seen at 55 hospitals and 107 emergency department (ED) or urgent care (UC) sites through Kaiser Permanente Northern California, Intermountain Healthcare in Utah, and HealthPartners in Minnesota and Wisconsin.
40% protection against hospital cases
The VE for vaccinated children against emergency department and urgent care (ED/UC) visits was 48% (95% confidence interval [CI], 44% to 52%). The study showed that 15.2% of vaccinated kids and 27.1% unvaccinated children made up ED/UC flu patients.
The VE against hospital admission for the flu was 40%. Among kids hospitalized for the flu, 17.5% were vaccinated and 33.4% were unvaccinated. The authors of the study said lower VE may be due to lower vaccine coverage.
The atypically early start of the 2022–2023 influenza season may have resulted in lower observed vaccine coverage.
"The atypically early start of the 2022–2023 influenza season may have resulted in lower observed vaccine coverage, as activity started and peaked before many children and adolescents may have had an opportunity to get vaccinated," they wrote.
High-dose fluvoxamine did not shorten COVID recovery times
News brief
48 minutes ago.
Stephanie Soucheray, MA
Topics
COVID-19
Results from arandomized clinical trial today of 1,208 participants show that high-dose (100-milligram [mg]) fluvoxamine did not improve time to sustained recovery in people with mild to moderate COVID-19 infections.
Fluvoxamine, known as Luvox, is a selective-serotonin reuptake inhibitor. Its potential use for COVID-19 was considered as part of the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV-6) platform, which aims to investigate repurposed medications in the outpatient setting for mild to moderate COVID-19.
The study is published in JAMA.
Participants were enrolled from August 25, 2022, to January 20, 2023, and were 30 years or older with confirmed SARS-CoV-2 infection and at least two acute COVID-19 symptoms for 7 days or less. The participants were randomized to receive fluvoxamine 50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days (601 patients), or a placebo (607).
The primary outcome was time to 3 consecutive days without symptoms.
All patients recovered in 10 to 11 days
The participants' average age was 50 years old, 65.8% were women, 45.5% identified as Hispanic/Latino, and 76.8% reported receiving at least two doses of a SARS-CoV-2 vaccine.
The authors found no differences among the study participants in time to recovery (adjusted hazard ratio, 0.99; 95% credible interval, 0.89 to 1.09), with both groups achieving sustained recovery by days 10 or 11. No participants died during the study, and fluvoxamine was not associated with any adverse events.
In an editorial on the study, two JAMA deputy editors wrote that the ACTIV trial is a success story of the pandemic. They note that shortly after the pandemic began, "the ACTIV platform also quickly began generating key insights for outpatient management of COVID-19 infection, such as the ineffectiveness of ivermectin."
They suggest the model should be used to investigate treatments to several outpatient diseases in addition to COVID.
MSF details mpox outbreak in DR Congo
News brief
Today at 2:47 p.m.
Mary Van Beusekom, MS
Topics
Mpox
Medecins Sans Fronteires (MSF, or Doctors Without Borders) said yesterday that it battled an mpox outbreak in the Democratic Republic of the Congo (DRC)'s Equateur province from August to mid-October.
An emergency team was in the Bolomba health zone in the western DRC to help health officials treat 890 mpox patients, provide education, contain spread of the virus, support 11 remote health centers, and conduct surveillance. Seventy-two patients (8.1%) were hospitalized.
Mpox, which is characterized by skin lesions, can be accompanied by fever, sore throat, muscle aches, or lymph-node pain.
"If the disease is not treated in time, it can lead to complications and death in those affected, especially if their immune system is compromised by other diseases," Raphael Kibwantiaka, head of MSF's emergency response in Bolomba, said in a news release. "As Bolomba was already grappling with a measles epidemic, we intervened against both diseases."
Measles, malnutrition, malaria
The workers followed up with more than 800 mpox patients at home and organized awareness-raising activities in healthcare facilities and the community to prevent disease transmission and combat stigma, "as the disease has highly visible signs on the body, sometimes leading to the rejection of patients by the community," Kibwantiaka said.
The emergency team vaccinated 110,723 children against measles and treated 3,355 others. They also treated 827 malnourished children and 2,583 with malaria.
The disease has highly visible signs on the body, sometimes leading to the rejection of patients by the community.
Staff sometimes had to travel by canoe or motorcycle, often in the rain. Kibwantiaka said Bolomba's remote, densely wooded environment is rich in wildlife, which makes it conducive for the development of diseases with animal origins, such as mpox.
"Eating bushmeat, handling dead animals, and animal bites or scratches encourage the transmission of the virus from animals to humans," he said. "Infected individuals then become highly contagious and need to isolate themselves quickly to prevent widespread transmission."
ALL BRIEFS